Accord BioPharma Inc, the US specialty division of India-based Intas Pharmaceuticals Ltd, announced on Monday that Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from California-based Coherus BioSciences Inc, a commercial-stage biopharmaceutical company.
A biosimilar to Neulasta (pegfilgrastim), UDENYCA expands the company's portfolio of FDA-approved products and accelerates Accord BioPharma's growth in the biosimilar industry. It is available in three administration options -- autoinjector (AI), on-body injector (OBI) and prefilled syringe (PFS) -- to provide flexibility for patients to receive their treatment at home, on-the-go or in the office.
Following the acquisition, Accord BioPharma will continue to make UDENYCA available to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval